TNTL for diabetic eye disease (non-proliferative)
Part of Eyes & vision clinical trials.
This study tests if a drug called TNTL can help people with type 2 diabetes who have early-stage diabetic eye disease (non-proliferative diabetic retinopathy) without severe vision loss. It aims to see if the treatment is safe and effective in slowing or improving the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have type 2 diabetes and have been told you have mild or moderate non-proliferative diabetic retinopathy (NPDR - an early stage of diabetic eye disease).
- Your vision in the eye being studied is still good (at least 20/200 on a vision chart).
- You have not had any severe eye diseases like macular edema, glaucoma, or retinal detachment.
- Your blood sugar control is fair (HbA1c level of 8.5% or lower in the last few months).
- You agree to follow the study procedures, including taking the study drug and attending visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an eye implant (OTX-TKI) that slowly releases a medicine to slow or stop worsening of non-proliferative diabetic retinopathy (NPDR) — an early form of diabetic eye disease. It's for people with moderately severe to severe NPDR who haven't had significant treatments like laser or injections in that eye.
This study tests if a simple, non-invasive treatment called remote ischemic conditioning (briefly restricting blood flow to one arm using a special cuff) can help slow down early-stage diabetic eye disease in people with type 2 diabetes. You join the study to potentially prevent your retinopathy from getting worse.
This trial tests if a targeted laser treatment guided by a special eye scan can slow the progression of blocked blood vessels in the retina for people with diabetes-related eye disease. It may help preserve vision by treating damaged areas before they worsen.
This trial tests whether an extract from the ginkgo tree can help prevent or slow vision loss in people with diabetes who have early signs of diabetic retinopathy. It is for patients who have not yet received eye treatments like laser or injections.
This study closely follows people with type 2 diabetes who have early signs of diabetic retinopathy (damage to the retina from diabetes) to see how the condition changes over time. It does not test a new treatment but monitors the eye's health closely. It may be a good fit if you have diabetic retinopathy that does not need immediate treatment.
This trial tests a type of laser treatment (DSLT) for people of Asian descent who have normal tension glaucoma, where eye pressure stays below 21 mmHg. It aims to see if this laser can help control the disease and possibly reduce the need for eye drops.
Hear when a new Non-Proliferative Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.